Loading organizations...
AdBio partners is a venture capital firm based in Paris, France, that specializes in seed-stage and early-stage investments for life sciences and biotechnology startups across the European market. The firm focuses on therapeutics-oriented companies developing treatments in oncology, immunology, and rare diseases, frequently collaborating directly with academic research institutions to build new enterprises from the ground up. AdBio partners manages over €170 million in assets under management across multiple investment vehicles, including a €102 million second fund that officially closed in late 2021. Backed by major institutional limited partners such as Bpifrance and the European Investment Fund, the firm has executed 26 investments to date. Its active portfolio of 22 companies includes emerging biotechnology startups like AgomAb Therapeutics, Tridek-One, and Alderaan. The firm was originally founded in 2016 by Alain Huriez and Matthieu Coutet.
Key people at AdBio partners.
AdBio Partners is a Paris-based venture capital firm specializing in early-stage investments in promising life sciences startups across Europe, with a strong entrepreneurial spirit focused on biotechnology and healthcare innovation.[1][2][4] Its mission is to source breakthrough medical discoveries from leading research institutions and technology transfer offices, partnering with scientific founders to build sustainable companies addressing unmet medical needs in areas like oncology, immunology, ophthalmology, rare diseases, and more.[1][2][3] The investment philosophy combines business, scientific, and financial expertise to identify and develop first- or best-in-class therapeutics, leveraging a network of scientific, industrial, and international VC partners to drive startups toward success and advance patient care.[1][2]
AdBio impacts the startup ecosystem by acting as both investors and entrepreneurs, creating companies from academic projects and providing hands-on support to accelerate innovation in Europe's life sciences sector.[1][4]
AdBio Partners operates from Paris, France, as a VC firm dedicated to company creation and early-stage biotechnology investments, though specific founding year and key partners are not detailed in available sources.[1][4] The firm's evolution centers on a unique approach blending entrepreneurial drive with investment, building a team of experts to collaborate with academic institutions and turn promising therapeutic ideas into viable startups.[1][2] This focus on sourcing innovations across therapeutic areas like cardiovascular, neuroinflammation, and cystic fibrosis has led to a diverse portfolio, humanizing its role through close ties with founders and researchers.[3]
AdBio Partners rides the wave of Europe's growing life sciences innovation, particularly in biotech therapeutics amid rising demand for solutions to unmet needs in oncology, autoimmune diseases, and rare conditions.[1][3] Timing aligns with increased academic-to-commercial translation, fueled by advancements in gene editing, cell therapy, and engineered biologics, where market forces like aging populations and post-pandemic healthcare investments favor agile early-stage backers.[2][3] By bridging research institutions with industry, AdBio influences the ecosystem by accelerating pipeline builders (e.g., AndzonBio initiatives) and platforms (e.g., Astraveus microfluidics), fostering a denser network of European biotech startups competitive on the global stage.[1][3]
AdBio Partners is poised to expand its portfolio in high-growth areas like cell/gene therapies and precision cytokines, capitalizing on Europe's biotech momentum and syndication opportunities.[1][3] Trends such as AI-driven drug discovery and regulatory tailwinds for orphan drugs will shape its trajectory, potentially amplifying influence through more thematic pipeline companies. As it scales, expect deeper impact on healthcare innovation, evolving from niche investor to key shaper of tomorrow's European life sciences leaders—building directly on its entrepreneurial roots in biotech.[1][2]
AdBio partners has 2 tracked investments across 2 companies. The latest tracked deal is $3.2M Seed in Orikine Bio in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 2, 2026 | Orikine Bio | $3.2M Seed | — | Asabys Partners, CDTI Innovación's INNVIERTE Program |
| Jan 28, 2026 | Tenpoint Therapeutics | $85.0M Series B | British Business Bank, EQT, Hillhouse Investment, Janus Henderson Investors | Eight Roads Ventures, EQT Life Sciences, F Prime, Qiming Venture Partners USA, Sofinnova Partners, Wille Finance |
Key people at AdBio partners.
